Robert Benjamin Stein
Chief Medical OfficerDr. Robert Benjamin Stein, also known as Bob, Ph.D., M.D., served as Member of Scientific Advisory Board of Autobahn Labs, Inc. until December 2025 and serves as its Advisor. Dr. Stein is Member of Scientific Advisory Board of Normunity Inc. from March 2026. He is Member of Scientific Advisory Board at AI Proteins, Inc. from October 2023. He serves as Member of Advisory Board for Agenus Inc. since 2023. He was the Founder & Senior R&D Advisor at Flame Biosciences Inc. He serves as Director of ImmunoGenesis, Inc. He serves as Senior Medical Advisor at Isosceles Pharmaceuticals, Inc. and has been its Member Board of Directors since June 2019. He serves as Member of the Scientific Advisory Board at MiNK Therapeutics, Inc. He served as Chief Medical Officer at Protagenic Therapeutics, Inc. Dr. Stein served as Executive Vice President of Research and Development at MiMedx Group, Inc. from August 10, 2020 to April 2022 and serves as its President of Regenerative Medicine & Biologics Innovation since April 2022. He joined MiMedx Group, Inc. in August 2020. He serves as Venture Partner at Samsara BioCapital, LLC. since January 2018. He is the Principal Consultant at RBS Biotech Consulting, LLC, which he founded in August 2008. He served as Senior Advisor of R&D at AgenTus from March 2017 to October 2019. During this time, Agenus advanced 13 monoclonal antibodies into the clinic and formed significant Partnerships with Incyte, Merck, UCB and Gilead. He is Scientific Advisory Board Member at MiroBio Ltd. He served as Senior R&D Advisor at Agenus Inc. from March 2017 to October 2019 and served as its President of Research and Development from September 2015 to March 2017. He helped shape clinical development strategy for vaccines and adjuvants. Additionally, he led integration of the 4-Antibody, PhosImmune and Xoma Pilot Plant acquisitions. He serves as a Director at Autobahn Labs. He is a Independent Non-Employee Director at PolyPid Ltd. since June 2020. He is an Independent Director at Taro Pharmaceutical Industries Ltd since February 2020. He serves as scientific adviser to Takeda Pharmaceutical Co. Ltd. He has experience and accomplishments to the Agenus leadership team. He is an innovative and experienced executive with deep, broad knowledge of biology, medicine and pharmaceutical science. Dr. Stein led Agenus' Research, Pre-clinical Development and Translational Medicine functions and guided its clinical development. In addition, pending closing, he plays a critical role in leading the integration of the 4-Antibody acquisition, which includes the company's fully human antibody drug discovery and optimization technology platform and portfolio of immune checkpoint antibody programs. He served as the Chief Executive Officer of KineMed, Inc. from August 01, 2008 to May 2010. Following Kinemed, from January 2014 to September 2015, he served as Chief Scientific Officer. He served as President of Roche Palo Alto LLC from September 2003 to January 2007. Dr. Stein served as President and Chief Scientific Officer of Incyte Corporation since November 2001 until August 22, 2003. He previously served as the Chief Scientific Officer and Head of Research and Development of Agenus Inc. from January 2014 to January 27, 2016. He served as Executive Director and Head of Pharmacology at Merck Sharp & Dohm. Dr. Stein served as Executive Vice President of Research and Preclinical Development of DuPont Pharmaceuticals Company, formerly The DuPont Merck Pharmaceutical Company, from 1996 to November 2001. He has experience in research and development and business roles with pharmaceutical and biotechnology companies. He has led R&D across all the major therapeutic areas and has made significant contributions to over nine registered medicines and thirteen monoclonal antibodies in late-stage clinical development. He served as Executive Vice President of Research and Pre-clinical Development for DuPont-Merck and DuPont pharmaceuticals since 1996. From 1990 to 1996 he served as the first Head of Research and Development for Ligand Pharmaceuticals. He served as Senior Vice President and Chief Scientific Officer from May 1990 to September 1996 and Vice President of Research and Preclinical Development from 1992 to 1993 and Vice President of Research for Ligand Pharmaceuticals, Inc. from 1990 to 1992. He spent the early part of his career at Merck, Sharp and Dohme Research Laboratories from 1982 to 1990 with contributions to three new products, Cozaar (a prescription drug), Sustiva (an HIV antiviral) and Gardasil (a vaccine). He was Senior Vice President of Research for Ligand Pharmaceuticals. He held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. From November 2001 to September 2003 he served as President, R&D and Chief Scientific Officer of Incyte Pharmaceuticals. He held various positions with Merck & Co., Sharp & Dohme Research Laboratories from 1982 to 1990, which included Senior Director and Head of the Department of Pharmacology from 1989 to 1990. He serves on the President's Board of Advisors for Science and Innovation for the University of California. Dr. Stein has been Director of Archemix Corp. since April 03, 2007. He had been a Director of Protagenic Therapeutics, Inc (formerly known as Atrinsic, Inc) since February 12, 2016 until May 15, 2025 and served as its Chief Scientific Advisor. He serves as a Director of Incyte Genomics. He served as a Director of DiaDexus, Inc. He is a Member of the College of American Pathology, the New York Academy of Sciences, the American Association of Cancer Research and the American Society of Clinical Oncology. He served as a Director of KineMed, Inc. since August 1, 2008. He served as Director of Incyte Corporation from 2001 to August 21, 2003. He served as Director of Geron Corporation from April 1996 to September 2, 2003. He has experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta® and Eliquis®. He is a Member of the Scientific Advisory Board for the Drug Development Institute of the James Comprehensive Cancer Center of Ohio State University. He is a Member of Phi Beta Kappa, Alpha Omega Alpha and Sigma Xi Honor Societies. He completed residency training and is Board certified in anatomic and clinical pathology. Dr. Stein holds B.S. in Biology and Chemistry from Indiana University, where he was a National Merit Scholar. He also holds M.D. and Ph.D. in Physiology and Pharmacology from Duke University Medical and Graduate Schools.
Positions
- Company NameProtagenic Therapeutics, Inc.Stock CodePTIXPositionChief Medical Officer
